IL175611A0 - Combinations for the treatment of proliferative diseases - Google Patents
Combinations for the treatment of proliferative diseasesInfo
- Publication number
- IL175611A0 IL175611A0 IL175611A IL17561106A IL175611A0 IL 175611 A0 IL175611 A0 IL 175611A0 IL 175611 A IL175611 A IL 175611A IL 17561106 A IL17561106 A IL 17561106A IL 175611 A0 IL175611 A0 IL 175611A0
- Authority
- IL
- Israel
- Prior art keywords
- combinations
- treatment
- proliferative diseases
- proliferative
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51955103P | 2003-11-12 | 2003-11-12 | |
| US10/855,130 US20050100508A1 (en) | 2003-11-12 | 2004-05-27 | Methods for identifying drug combinations for the treatment of proliferative diseases |
| PCT/US2004/037527 WO2005046607A2 (en) | 2003-11-12 | 2004-11-09 | Combinations for the treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL175611A0 true IL175611A0 (en) | 2008-04-13 |
Family
ID=34556562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL175611A IL175611A0 (en) | 2003-11-12 | 2006-05-11 | Combinations for the treatment of proliferative diseases |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1689352A2 (en) |
| JP (1) | JP2007524657A (en) |
| KR (1) | KR20060118514A (en) |
| AR (1) | AR046841A1 (en) |
| AU (1) | AU2004289311A1 (en) |
| BR (1) | BRPI0416390A (en) |
| CA (1) | CA2545423A1 (en) |
| IL (1) | IL175611A0 (en) |
| IS (1) | IS8496A (en) |
| NO (1) | NO20062358L (en) |
| RU (1) | RU2006120491A (en) |
| TW (1) | TW200526777A (en) |
| WO (1) | WO2005046607A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY166445A (en) * | 2008-03-18 | 2018-06-27 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| US6569853B1 (en) * | 2000-11-06 | 2003-05-27 | Combinatorx, Incorporated | Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders |
-
2004
- 2004-11-05 TW TW093133826A patent/TW200526777A/en unknown
- 2004-11-09 CA CA002545423A patent/CA2545423A1/en not_active Abandoned
- 2004-11-09 AU AU2004289311A patent/AU2004289311A1/en not_active Abandoned
- 2004-11-09 EP EP04810676A patent/EP1689352A2/en not_active Withdrawn
- 2004-11-09 KR KR1020067010335A patent/KR20060118514A/en not_active Withdrawn
- 2004-11-09 WO PCT/US2004/037527 patent/WO2005046607A2/en not_active Ceased
- 2004-11-09 BR BRPI0416390-7A patent/BRPI0416390A/en not_active Application Discontinuation
- 2004-11-09 JP JP2006539813A patent/JP2007524657A/en active Pending
- 2004-11-09 RU RU2006120491/15A patent/RU2006120491A/en not_active Application Discontinuation
- 2004-11-12 AR ARP040104188A patent/AR046841A1/en unknown
-
2006
- 2006-05-11 IL IL175611A patent/IL175611A0/en unknown
- 2006-05-23 NO NO20062358A patent/NO20062358L/en not_active Application Discontinuation
- 2006-06-02 IS IS8496A patent/IS8496A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0416390A (en) | 2007-02-21 |
| AU2004289311A1 (en) | 2005-05-26 |
| TW200526777A (en) | 2005-08-16 |
| AR046841A1 (en) | 2005-12-28 |
| WO2005046607A2 (en) | 2005-05-26 |
| EP1689352A2 (en) | 2006-08-16 |
| JP2007524657A (en) | 2007-08-30 |
| NO20062358L (en) | 2006-07-12 |
| KR20060118514A (en) | 2006-11-23 |
| CA2545423A1 (en) | 2005-05-26 |
| RU2006120491A (en) | 2007-12-20 |
| WO2005046607A3 (en) | 2012-12-20 |
| IS8496A (en) | 2006-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227841A0 (en) | Dihydropteridinones for the treatment of cancer diseases | |
| IL179508A0 (en) | 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders | |
| IL176028A0 (en) | Compounds for treatment of cell proliferative diseases | |
| PL1976886T3 (en) | Means and methods for the treatment of tumorous diseases | |
| ZA200508427B (en) | Methods for treating interleuking-6 related diseases | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| GB0316912D0 (en) | Therapeutic treatment | |
| PL1685125T3 (en) | Pyrrole derivatives useful for the treatment of proliferative diseases | |
| GB0320806D0 (en) | Therapeutic treatment | |
| GB0329874D0 (en) | Compounds useful for the treatment of diseases | |
| EP1611120A4 (en) | Novel methods for the treatment of inflammatory diseases | |
| ZA200806095B (en) | Means and methods for the treatment of tumorous diseases | |
| GB0329275D0 (en) | Therapeutic treatment | |
| GB0307863D0 (en) | Therapeutic treatment | |
| GB0313772D0 (en) | Therapeutic treatment | |
| IL175611A0 (en) | Combinations for the treatment of proliferative diseases | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| SI1535612T1 (en) | Treatment for hyperuricemia | |
| GB0216097D0 (en) | Treatment of proliferative disorders | |
| GB0420867D0 (en) | Compounds for the treatment of diseases | |
| IL177531A0 (en) | Compounds for the treatment of diseases | |
| GB0425073D0 (en) | Compounds for the treatment of diseases | |
| GB0425064D0 (en) | Compounds useful for the treatment of diseases | |
| AP2006003743A0 (en) | Compounds useful for the treatment of diseases | |
| GB0324482D0 (en) | Methods for the treatment of cancer |